Clinical Trials

NeoImmuneTech gets IND clearance for NT-I7 trial in locally recurrent SCCHN

NeoImmuneTech announced receipt of IND clearance from the US Federal Drug Administration (FDA) to evaluate NT-I7 (efineptakin alfa), the only clinical-stage long-acting human IL-7, in a Window-of-Opportunity trial for patients with locally recurrent squamous cell carcinoma of head and neck (SCCHN) undergoing salvage surgery.

Pfizer, BioNTech begin phase 2/3 Covid-19 trial with BNT162b2 vaccine candidate

Pfizer, along with BioNTech, has commenced the phase 2/3 safety and efficacy clinical study to assess a single nucleoside-modified messenger RNA (modRNA) candidate from their BNT162 mRNA-based vaccine programme against SARS-CoV-2.

Inotrem gets clearance to launch phase 2 trial of Nangibotide in Covid-19 patients

Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway, announced that it has obtained authorization to launch its phase IIa clinical trial in COVID-19 patients in France, Belgium and the USA.

Medidata supports Moderna’s Covid-19 vaccine clinical trials with Rave clinical cloud platform

Medidata, a Dassault Systèmes company, the global leader in creating end-to-end solutions supporting the entire clinical trial process, announced that it is collaborating with Moderna to support clinical trials of mRNA-1273, Moderna’s COVID-19 vaccine candidate.

Humanetics gets financing from NIAID to study BIO 300 drug in Covid-19 patients

Clinical-stage pharmaceutical company Humanetics has secured financing from the National Institute of Allergy and Infectious Diseases (NIAID) to carry out a test with its BIO 300 drug in Covid-19 patients.

7000RMS Services

Expert system services provide peace of mind and ensure that your analyzer is performing optimally to deliver process control.

XyloCor doses patients in phase 1/2 trial evaluating XC001 in refractory angina

XyloCor Therapeutics announced it has successfully dosed the first two patients in the EXACT Trial, a Phase 1/2 dose escalation trial evaluating the safety, tolerability and efficacy of its lead candidate XC001 in patients with refractory angina.

AZD1222 delivers strong immune response in phase I/II Covid-19 vaccine trial

AstraZeneca said that the AZD1222 vaccine candidate (formerly ChAdOx1 nCoV-19) licensed from the Oxford University has shown strong immune responses against the SARS-CoV-2 virus in all participants in a phase I/II trial.

ADC Therapeutics begins phase 2 portion of LOTIS 3 trial of Lonca, ibrutinibhave combo

ADC Therapeutics announced that the first patient has been dosed in the pivotal Phase 2 portion of LOTIS 3, a Phase 1/2 clinical trial evaluating loncastuximab tesirine (Lonca, formerly ADCT-402) in combination with ibrutinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL).